A Pilot Open-label, Randomized, Crossover, Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ (Test Product) Relative to INBRIJA® (Reference Product) in Healthy Adult Subjects
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Levodopa (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors PureIMS
- 18 Jan 2024 According to a PureIMS media release, based on data from this study the company getting ready for an abbreviated registration path, which was determined in consultation with the FDA.
- 26 Oct 2023 Status changed from active, no longer recruiting to completed.
- 28 Sep 2023 Planned End Date changed from 9 Oct 2023 to 23 Oct 2023.